Resmed (RSMDF) Receivables (2010 - 2026)

Resmed has reported Receivables for 17 years, with the latest figure at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 9.01% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (up 9.01% YoY), and the FY2025 full-year result was $990.7 million, up 13.16% from the prior year.
• Receivables for Q1 2026 stood at $1.0 billion, roughly flat from $1.0 billion in the prior quarter.
• The five-year high for Receivables was $1.0 billion in Q4 2025, with the low at $534.2 million in Q1 2022.
• Historically, Receivables has averaged $815.9 million across 5 years, with a median of $817.2 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables slipped 3.77% — and 2023, when it surged 33.31%.
• Resmed's Receivables stood at $695.4 million in 2022, then gained by 9.91% to $764.3 million in 2023, then advanced by 18.66% to $907.0 million in 2024, then grew by 15.45% to $1.0 billion in 2025, then slipped by 0.11% to $1.0 billion in 2026.
• The last three Receivables figures came in at $1.0 billion (Q1 2026), $1.0 billion (Q4 2025), and $958.4 million (Q3 2025), per Business Quant data.